| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV substudy.
|
Circulation
|
2003
|
4.31
|
|
2
|
Facilitated PCI in patients with ST-elevation myocardial infarction.
|
N Engl J Med
|
2008
|
2.61
|
|
3
|
Troponin T levels and risk of 30-day outcomes in patients with the acute coronary syndrome: prospective verification in the GUSTO-IV trial.
|
Am J Med
|
2003
|
1.81
|
|
4
|
Influence of functional deficiency of complement mannose-binding lectin on outcome of patients with acute ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention.
|
Eur Heart J
|
2010
|
1.76
|
|
5
|
Troponin and C-reactive protein have different relations to subsequent mortality and myocardial infarction after acute coronary syndrome: a GUSTO-IV substudy.
|
J Am Coll Cardiol
|
2003
|
1.75
|
|
6
|
Academic health leadership: looking to the future. Proceedings of a workshop held at the Canadian Institute of Academic Medicine meeting Québec, Que., Canada, Apr. 25 and 26, 2003.
|
Clin Invest Med
|
2003
|
1.61
|
|
7
|
Outcomes of patients in clinical trials with ST-segment elevation myocardial infarction among countries with different gross national incomes.
|
Eur Heart J
|
2006
|
1.59
|
|
8
|
Physical activity in patients with stable coronary heart disease: an international perspective.
|
Eur Heart J
|
2013
|
1.53
|
|
9
|
Intraluminal thrombus in facilitated versus primary percutaneous coronary intervention: an angiographic substudy of the ASSENT-4 PCI (Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Intervention) trial.
|
J Am Coll Cardiol
|
2011
|
1.45
|
|
10
|
Enoxaparin in primary and facilitated percutaneous coronary intervention A formal prospective nonrandomized substudy of the FINESSE trial (Facilitated INtervention with Enhanced Reperfusion Speed to Stop Events).
|
JACC Cardiovasc Interv
|
2010
|
1.45
|
|
11
|
Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia.
|
Circulation
|
2008
|
1.39
|
|
12
|
Should cities hosting mass gatherings invest in public health surveillance and planning? Reflections from a decade of mass gatherings in Sydney, Australia.
|
BMC Public Health
|
2009
|
1.23
|
|
13
|
Outbreaks of pandemic (H1N1) 2009 and seasonal influenza A (H3N2) on cruise ship.
|
Emerg Infect Dis
|
2010
|
1.04
|
|
14
|
Troponin-T and N-terminal pro-B-type natriuretic peptide predict mortality benefit from coronary revascularization in acute coronary syndromes: a GUSTO-IV substudy.
|
J Am Coll Cardiol
|
2006
|
1.02
|
|
15
|
Large streamlined trials in cardiovascular disease.
|
Eur Heart J
|
2014
|
1.01
|
|
16
|
A rapid troponin I assay is not optimal for determination of troponin status and prediction of subsequent cardiac events at suspicion of unstable coronary syndromes.
|
Int J Cardiol
|
2004
|
0.93
|
|
17
|
Facilitated percutaneous coronary intervention versus primary percutaneous coronary intervention: design and rationale of the Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events (FINESSE) trial.
|
Am Heart J
|
2004
|
0.93
|
|
18
|
A letter from CMAJ's editorial board to the CMA.
|
CMAJ
|
2002
|
0.90
|
|
19
|
Pseudoaneurysm of the superficial femoral artery associated with osteochondroma--a case report.
|
Vasc Endovascular Surg
|
2005
|
0.88
|
|
20
|
Influenza outbreak during Sydney World Youth Day 2008: the utility of laboratory testing and case definitions on mass gathering outbreak containment.
|
PLoS One
|
2009
|
0.88
|
|
21
|
Usefulness of biomarkers for predicting long-term mortality in patients with diabetes mellitus and non-ST-elevation acute coronary syndromes (a GUSTO IV substudy).
|
Am J Cardiol
|
2005
|
0.87
|
|
22
|
1-year survival in a randomized trial of facilitated reperfusion: results from the FINESSE (Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events) trial.
|
JACC Cardiovasc Interv
|
2009
|
0.86
|
|
23
|
Prescribing errors in general practice: a prospective study.
|
Eur J Gen Pract
|
2009
|
0.84
|
|
24
|
A mixed-methods prospective study of death certification in general practice.
|
Fam Pract
|
2010
|
0.82
|
|
25
|
Supervised exercise training improves aerobic capacity and muscle strength in older women with heart failure.
|
Can J Cardiol
|
2005
|
0.81
|
|
26
|
Technical factors affecting the accuracy of bedside IVC filter placement using intravascular ultrasound.
|
Vasc Endovascular Surg
|
2012
|
0.81
|
|
27
|
Graft infectivity of rifampin and silver-bonded polyester grafts to MRSA contamination.
|
Vasc Endovascular Surg
|
2005
|
0.80
|
|
28
|
Efficacy of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: one-year follow-up results of the Assessment of the Safety of a New Thrombolytic-3 (ASSENT-3) randomized trial in acute myocardial infarction.
|
Am Heart J
|
2004
|
0.79
|
|
29
|
Synthesis and in vitro and in vivo evaluation of a series of dihydroisocoumarin derivatives conjugated with fatty acids, alcohols, and amines as potential anticancer agents.
|
Bioconjug Chem
|
2009
|
0.79
|
|
30
|
"No one dies of old age": implications for research, practice, and policy.
|
J Palliat Care
|
2011
|
0.79
|
|
31
|
Growth inhibitory activity of extracted material and isolated compounds from the fruits of Kigelia pinnata.
|
Planta Med
|
2010
|
0.79
|
|
32
|
One-year follow-up of the ASSENT-2 trial: a double-blind, randomized comparison of single-bolus tenecteplase and front-loaded alteplase in 16,949 patients with ST-elevation acute myocardial infarction.
|
Am Heart J
|
2003
|
0.79
|
|
33
|
Impact of TIMI 3 patency before primary percutaneous coronary intervention for ST-elevation myocardial infarction on clinical outcome: results from the ASSENT-4 PCI study.
|
Eur Heart J Acute Cardiovasc Care
|
2012
|
0.78
|
|
34
|
Proceedings of the 99th meeting of the Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee. May 29th and 30th, 2003.
|
Circulation
|
2003
|
0.78
|
|
35
|
Cost effectiveness in Canada of eptifibatide treatment for acute coronary syndrome patients using PURSUIT subgroup analysis.
|
Can J Cardiol
|
2003
|
0.78
|
|
36
|
Rapid stereoselective access to key pumiliotoxin precursors from a common intermediate.
|
J Org Chem
|
2004
|
0.78
|
|
37
|
The early glycoprotein IIb/IIIa inhibition in non-ST-segment elevation acute coronary syndrome (EARLY ACS) trial: a randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non-ST-segment elevation acute coronary syndrome--study design and rationale.
|
Am Heart J
|
2005
|
0.78
|
|
38
|
Analysis of oxidizer salt mixtures by electrospray ionization mass spectrometry.
|
Rapid Commun Mass Spectrom
|
2006
|
0.78
|
|
39
|
Activation of the inflammation, coagulation, and fibrinolysis systems, without influence of abciximab infusion in patients with non-ST-elevation acute coronary syndromes treated with dalteparin: a GUSTO IV substudy.
|
Am Heart J
|
2004
|
0.76
|
|
40
|
Analysis of maize ( Zea mays ) kernel density and volume using microcomputed tomography and single-kernel near-infrared spectroscopy.
|
J Agric Food Chem
|
2013
|
0.76
|
|
41
|
Electrocardiographic identification of the culprit coronary artery in inferior wall ST elevation myocardial infarction.
|
Can J Cardiol
|
2010
|
0.75
|
|
42
|
Retroperitoneal lymph node dissection with concomitant IVC thrombectomy, caval wall resection, and grafting for metastatic NSGCT.
|
Int Braz J Urol
|
2012
|
0.75
|
|
43
|
From the hospital to the home - the rise and rise of Clostridium difficile infection.
|
Aust Fam Physician
|
2015
|
0.75
|
|
44
|
Alcohol restrictions and STIs: is there a link?
|
Aust N Z J Public Health
|
2011
|
0.75
|
|
45
|
An introduction to avian and pandemic influenza.
|
N S W Public Health Bull
|
2006
|
0.75
|